



RESI EUROPE 2026

March 23: In-person at EPIC SANA Lisboa Hotel | March 24-25, 30-31: Virtual Partnering



PRESENTED BY



**LIFE SCIENCE
NATION**

Connecting Products, Services & Capital

ONSITE GUIDE

Capital investors, licensing partners, fundraising CEOs, and service providers **Make a Compelling Connection**

TITLE SPONSORS



RESIConference.com | EPIC SANA Lisboa
#RESI #RESIEUROPE

WELCOME TO RESI



Welcome to RESI Europe 2026 in Lisbon!

Life Science Nation (LSN) is pleased to bring together the global life science investment community for Redefining Every Stage of Investment (RESI) Europe at the EPIC SANA Lisboa Hotel in Lisbon, Portugal. This year's conference highlights the rapidly growing life science innovation ecosystem across Europe, providing a platform for life science companies to connect with investors and strategic partners.

The RESI Europe in-person agenda on Monday, March 23, will feature insightful investor panels, Innovator's Pitch Challenge (IPC) presentations, and workshops led by RESI sponsors and industry experts. These sessions provide practical insight into key areas such as valuation strategy, risk management, legal considerations, and capital formation. The IPC gives startups the opportunity to pitch live to an audience and a panel of experienced investor judges. LSN extends its appreciation to our Title Sponsors: Dealflow.eu, One Nucleus, ASEBIO, and BioMetas, as well as our Gold Sponsors: Venture Valuation, Medmarc, and Cuatrecasas, Silver Sponsor Europe Innovation Council (EIC), Bronze Sponsor OPIS. Their support helps facilitate meaningful connections between investors and innovators.

At its core, RESI is about matchmaking life science companies with the right capital, licensing, and channel partners. The RESI partnering platform enables targeted, high-value meetings based on key criteria, ensuring productive conversations. In-person partnering takes place on March 23 in Lisbon, with virtual partnering continuing March 24-25 and March 30-31, maximizing opportunities to connect with investors and strategic partners around the world. LSN looks forward to helping advance fundraising and strategic partnership goals through RESI Europe 2026.

Sougato Das

President and Chief Operating Officer

Life Science Nation





RESI CONFERENCE SERIES



RESI JUNE 2026

JUNE 22: SAN DIEGO, CA

JUNE 23-24, 29-30: VIRTUAL PARTNERING



RESI BOSTON 2026

SEPT 22-23: BOSTON, MA

SEPT 25, 28-29: VIRTUAL PARTNERING



RESI JPM 2027

JAN 11-12: SAN FRANCISCO, CA

JAN 13, 18-19: VIRTUAL PARTNERING


Take \$100 off with discount code **RESI100** for future RESIs.

For more information about our future events,

visit our website RESIConference.com or contact us at RESI@lifesciencenation.com.

Floor Plan

FLOOR -1



 **Sponsors & Exhibitors**

- 1 OneNucleus
- 2 Cuatrecasas
- 3 TMC Pharma
- 4 OPIS
- 5 Dealflow
- 6 ASEBIO
- 7 Venture Valuation
- 8 BioMetas
- 9, 10 Life Science Nation

 **Pitching Company Table**

- 1 Aligned Bio
- 2 MindLab
- 3 Spatial Surgical Inc.
- 4 AMETS BIOTECHNOLOGY
- 5 Alphyn Biologics
- 6 Exalt
- 7 Xintela
- 8 Nephrolyx GmbH
- 9 Wavefront Therapeutics
- 10 Genomill Health
- 11 PhotoPill Medical
- 12 ISPIRON Biotechnologies
- 13 Skymab Biotherapeutics
- 14 DARWIN Biomed
- 15 You2Yourself BV
- 16 Ternarx Pty Ltd
- 17 MAVATAR
- 18 StimOxyGen
- 19 FcR Therapeutics
- 20 AMPLEIA
- 21 Oncovita
- 22 TAUC3 BIOLOGICS LIMITED
- 23 Myonerv
- 24 Adheal
- 25 Ysium Medical
- 26 Complex
- 27 AIDDA B.V.

AGENDA

8 - 9 AM: Breakfast (Morus I) 9 AM - 5 PM: Partnering Forum (Morus II)			
	Investor Panels (Vitis II+III)	Innovator's Pitch Challenge (IPC) (Vitis I)	Entrepreneur's Workshops (Vitis IV)
9:00 AM - 9:50 AM	PHARMA PARTNERING: GETTING ON PHARMA'S RADAR	IPC SESSION #1 DIAGNOSTICS	 LIFE SCIENCE NATION <small>Connecting Products, Services & Capital</small> SCIENCE, SIGNAL, AND LEGIBILITY FOR GLOBAL FUNDRAISING
10:00 AM - 10:50 AM	FUNDING NEW SCIENCE: HOW VCS EVALUATE PRECLINICAL PROGRAMS	IPC SESSION #2 MEDICAL DEVICES	 European Innovation Council  EIC FUNDING OPPORTUNITIES OVERVIEW
11:00 AM - 11:50 AM	FAMILY OFFICES: THE RISE OF THE VENTURE BUILDER	IPC SESSION #3 THERAPEUTICS	TALES FROM THE ROAD <i>Biotech and MedTech Innovators on their Fundraising Journey</i>
12:00 PM - 1:00 PM	Lunch Break (Morus I)		
1:00 PM - 1:50 PM	BUILDING INVESTABLE MEDTECH: DEVICES, DIAGNOSTICS, AND DE- RISKING	IPC SESSION #4 DIAGNOSTICS	 VENTURE VALUATION <small>GLOBAL VALUATION SERVICES</small> COMPANY VALUATION FOR FUNDRAISING
2:00 PM - 2:50 PM	DIGITAL HEALTH: MOVING FROM HYPE TO SUSTAINABLE VALUE	IPC SESSION #5 THERAPEUTICS	 OKG Capital LEGIBILITY, SIGNAL, AND THE REAL WORK BETWEEN SEED AND SERIES B
3:00 PM - 3:50 PM	CAPITAL WITHOUT BORDERS: THE EUROPEAN LIFE SCIENCE LANDSCAPE	IPC SESSION #6 CELL & GENE THERAPY PLATFORMS	 CUATRECASAS NEGOTIATING TERM SHEETS
4:00 PM - 4:50 PM	BACKING THE FIRST BELIEVERS: DECIDING TO WRITE THE FIRST CHECK	IPC SESSION #7 THERAPEUTICS	 one nucleus DISCOVERY AND DEVELOPMENT OF INNOVATIVE RARE DISEASE MEDICINES
5:00 - 7:00 PM: Cocktail Reception - Announce IPC Winners (Foyer)			

SPONSORS & EXHIBITORS

Title Sponsors



Gold Sponsors



Silver Sponsor



Bronze Sponsor



Exhibitor



SPONSORS & EXHIBITORS



Table #5

At Dealflow.eu, we support the most promising EU-funded startup and innovations to scale up and grow. To do so, we leverage advance data platforms to select and connect the founders to key investors and corporations, and provide tailored support to capitalize on these connections. From thousands of applicants, our startups have received up to €2.5m in grants and €15m in equity thanks to EU support. These ready-to-scale companies have clean cap tables and drive innovations that seek aligned connections to grow across markets. If you would like to discover more about our startups dealflow or the support that we can provide to EU funded innovations, contact us at team@dealflow.eu



Table #6

The Spanish Bioindustry Association (AseBio) represents companies, associations, foundations, universities, and research centers involved in biotechnology across Spain. For over 25 years, AseBio has worked with regional, national, and European institutions to advance biotechnology, promote innovation, and support policies that strengthen Spain's biotech sector. The organization is committed to improving quality of life, environmental sustainability, economic growth, and the creation of high-value jobs through biotechnology. AseBio fosters collaboration and innovation within an inclusive ecosystem and is a member of EuropaBio, the European Association for Bioindustries, which represents more than 1,800 biotech companies across Europe.



Table #1

One Nucleus is a not-for-profit Life Sciences & Healthcare membership organisation headquartered in Cambridge. We support institutions, companies and individuals in the Life Sciences sector providing local, UK-wide and international connectivity. Through providing the local, UK-wide and international connectivity, One Nucleus seeks to enable our members to maximise their performance. This support helps them achieve, or better still exceed, the goals they have set for themselves. Biomedical and Healthcare R&D have always been impactful in driving social and economic progress. In an increasingly outsourced, collaborative and multi-disciplinary sector, bringing the best people together is key to translating great innovation into great products that markedly improve patient outcomes and drive economic development. Attracting and enabling the best people to engage with is at the heart of the One Nucleus team ethos and what we continually strive to deliver.



Table #8

BioMetas: Supporting the Next Generation of Therapeutic Startups
BioMetas is a trusted partner for early-stage biotech innovators, providing a comprehensive suite of preclinical research services. With expertise spanning in vitro biology, in vivo pharmacology, cancer biology, protein science, and immunology, BioMetas enables startups to progress their drug development programs efficiently. By streamlining the preclinical process and providing milestone-driven support, BioMetas helps biotech companies de-risk their assets and position them for successful global partnering opportunities.

SPONSORS & EXHIBITORS

Created in 1979 by the healthcare technology industry, Medmarc's mission is to be the superior provider of liability insurance protection and related risk management solutions to the medical technology industry. We support the research and development, manufacturing, and delivery of medical products that save lives and improve the quality of life. Through collaboration with our parent company, ProAssurance, and our strategic alliance carriers in the U.S. and abroad, we provide a single source of innovative healthcare liability insurance solutions to the life sciences companies we serve. From ideas and prototypes to the reality of commercialization and success – We Can Meet Your Changing Needs. Contact us to discuss the cost of insurance coverage and what coverages are needed for your business plan. (703) 652-1360



Table #7

Biotechgate is a leading business development and licensing database for the entire life science industry, offering a wealth of information on over 69,000 life science company profiles. Thanks to its unique data sourcing process, the profiles include company descriptions, contact information, product pipeline information, financing rounds, and management details, making it an invaluable resource for life sciences start-ups, pharma companies, investors, and other industry professionals. Biotechgate also features 30,000 licensing deals and a clinical trials database containing over 800,000 records from registries around the world.



Table #2

Cuatrecasas is an international law firm firmly established in Spain, Portugal and Latin America, where it has offices in Chile, Colombia, Mexico and Peru. With a multidisciplinary and diverse team of over 1,900 professionals from 29 nationalities, we cover all areas of business law with a sectoral approach, focusing on all types of business. Cuatrecasas has 27 offices in 13 countries and collaborates closely with leading law firms in other countries to offer a team to meet every client's needs in every scenario.



The European Innovation Council (EIC) is the EU's flagship program under Horizon Europe, with a €10.1 billion budget (2021–2027) to support breakthrough technologies and high-impact innovations. It funds early-stage research through EIC Pathfinder, technology maturation via EIC Transition, and market scaling for startups and SMEs with EIC Accelerator, which offers grants and equity investments. Beyond funding, the EIC provides Business Acceleration Services, including mentoring and global networking. Managed by the EIC Board and EISMEA, it fosters disruptive innovation across Europe. Learn more at eic.ec.europa.eu.

SPONSORS & EXHIBITORS



Table #4

OPIS, founded in 1998 by physicians from the pharmaceutical industry, is a global full-service CRO with 26 years of experience. The company provides end-to-end clinical trial support across Phase I–IV studies, including interventional, non-interventional, and medical device trials, as well as pre- and post-marketing studies for medical and diagnostic devices, nutraceuticals, and food supplements. With a dedicated team that has managed more than 1,500 studies, OPIS offers expertise in trial design, medical writing, statistics, and high-quality global execution across a broad range of therapeutic areas. OPIS operates through affiliates in 18 countries worldwide.



Table #3

TMC is a global pharma services company, partnering with small to mid-sized biotech and pharma companies to accelerate drug development timelines and maximise value across the full product lifecycle. We provide end-to-end support - from early stage clinical development to clinical execution, market access and drug commercialisation. Our integrated pharma services are delivered by cross-functional experts with extensive knowledge across regulatory, clinical development, medical services, pharmacovigilance and quality specialities. Whether you're advancing a rare disease treatment, pioneering an advanced therapeutic modality or preparing for market entry in the EU and UK, TMC is the pharma services company with the agility, insight and infrastructure to make it happen.



Insuring the Life Sciences Industry Since 1979

- Products Liability
- Clinical Trials Liability
- Manufacturers E&O

Phone: 888.633.6272 | Email: MedTechLifeSci@medmarc.com
4795 Meadow Wood Lane | Suite 335 West | Chantilly, VA 20151

LEARN MORE
medmarc.com



CUATRECASAS

Your legal partner for Venture Capital
in Portugal, Spain and Latin America.

cuatrecasas.com



A Science Driven Biotech Focused CRO


WHERE CLINICAL EXPERIENCE DRIVES TRIALS ON TIME

SCIENCE DRIVEN BIOTECH FOCUSED

FULL SERVICE CRO (PHASE I-IV)



27
YEARS OF LEADERSHIP



From Oncology to Rare Diseases
Advancing Medicine through
Operational Excellence

Global Presence. Local Delivery.

Clinical Operations Across
USA | Europe | Asia-Pacific



EMPOWERING BIOTECHS GLOBALLY

ACCELERATE YOUR STUDY WITH SMART DATA SOLUTIONS THE **MADE TO MEASURE** EDC System



Built for speed.
Designed for
compliance

Request a Demo
Visit clinical.net



WEB BASED

Access your study data anytime, anywhere.



CUSTOMIZABLE

Tailored workflows and forms built around your protocol needs.



USER FRIENDLY

Designed for simplicity. Intuitive for sites, monitors, and sponsors.



GCP, FDA & GDPR COMPLIANT

Validated, secure, and fully aligned with global regulatory standards.



+18 YEARS ON THE MARKET

A trusted platform with proven performance for nearly two decades.

RESI CONFERENCE SERIES PRESENTED BY LIFE SCIENCE NATION



Life Science Nation (LSN)

Life Science Nation has built a global partnering backbone that links early stage healthcare companies with capital investors and licensing partners. Our resources combine data, technology, education, and curated events to help innovators prepare for and execute global fundraising and partnering campaigns.

Table #9, 10

Key Resources

- GPC Platform + RESI Conference Series: Match with investors and partners by product, stage, and allocation needs across Drugs, Devices, Diagnostics, and Digital Health.
- Partner Network: Includes service providers, tech hubs, and agencies that power early-stage life sciences.
- Three Components: Investor & Licensing Partner Database integrated with Salesforce CRM, RESI Partnering Events, and Entrepreneurial Education.



Global Partnering Campaign (GPC)

The GPC combines LSN's investor/licensing database with Salesforce CRM. Subscribers receive a vetted Global Target List (GTL) of likely partners organized into priority tiers:

- Tier 1: Exact mandate fit
- Tier 2: Opportunistic investors seeking compelling assets
- Tier 3: Potential fits based on recent activity

Profiles update daily and integrate with CRM to track outreach, materials shared, notes, and investor pipeline reporting.



LSN BD Assist

BD Assist is LSN's managed global outreach program. We build and refine your global target list, integrate it into Salesforce CRM, develop messaging, launch coordinated outreach, and manage meeting scheduling. This enables founders to focus on development while we manage the time consuming work of investor engagement.

What BD Assist Delivers

- AI-optimized messaging for outreach
- Prioritized partner targeting
- Coordinated outreach campaigns
- Confirmed investor meetings synced to your CRM

With over a decade of experience teaching startups how to craft their story and secure funding, LSN combines trusted methodology with hands-on execution. Results speak for themselves: 90% of companies in our Australian accelerator cohort secured funding or partnerships.

If you're raising capital or licensing in the next 12 months, BD Assist is your turnkey solution for launching a global campaign without building an in-house BD team.


Contact us at salescore@lifesciencenation.com to get started.



LSN Publications

LSN publishes educational content and market insights to support early stage companies as they prepare for global fundraising. These publications highlight investor trends, partnering strategies, and best practices for telling a clear and compelling story.

NEXT PHASE»



INVESTOR PANELS

9:00 - 9:50 AM

PHARMA PARTNERING: GETTING ON PHARMA'S RADAR

With pharma companies leaning heavily on external R&D, the window for early-stage partnerships has never been wider. But what does it take to actually close a deal? This session examines how the industry's biggest players vet new science, which data points actually move the needle, and how startups can initiate BD conversations that lead to long-term strategy rather than one-off meetings.

10:00 - 10:50 AM

FUNDING NEW SCIENCE: HOW VCS EVALUATE PRECLINICAL PROGRAMS

The days of "funding for science's sake" are over. Today's VCs are prioritizing capital efficiency and clear differentiation. In this session, active therapeutic investors share how they quantify scientific risk and which milestones a founder must hit to stand out in a crowded Series A market.

11:00 - 11:50 AM

FAMILY OFFICES: THE RISE OF THE VENTURE BUILDER

Family offices have moved well beyond passive participation. By launching dedicated funds and building expert in-house teams, they are now leading early-stage healthcare rounds with a level of conviction and sector focus that rivals traditional VC. This discussion analyzes the mechanics of how these offices source deals and build portfolios, as well as the unique decision-making dynamics that set them apart from institutional venture firms.

1:00 - 1:50 PM

BUILDING INVESTABLE MEDTECH: DEVICES, DIAGNOSTICS, AND DE-RISKING

Medtech founders face a grueling gauntlet of regulatory hurdles and scaling challenges. Investors are looking for more than just a novel device—they want clinical relevance. This panel breaks down the current interest in minimally invasive tech and digital-enabled devices, focusing on the milestones that prove a platform is ready for prime time.

2:00 - 2:50 PM

DIGITAL HEALTH: MOVING FROM HYPE TO SUSTAINABLE VALUE

The digital health market has matured, and the “move fast and break things” era has been replaced by a demand for measurable outcomes. The session explores the sectors where investors see the most significant upside—such as AI-driven diagnostics and data platforms—and how founders can prove their tech has staying power in a real-world clinical setting.

3:00 - 3:50 PM

CAPITAL WITHOUT BORDERS: THE EUROPEAN LIFE SCIENCE LANDSCAPE

Europe is home to world-class research, but the funding environment is changing. As cross-border investment becomes the new norm, the panel will discuss how the European ecosystem is evolving to compete on a global scale and what it takes to attract international capital.

4:00 - 4:50 PM

BACKING THE FIRST BELIEVERS: DECIDING TO WRITE THE FIRST CHECK

The earliest investors essentially bet on a vision before meaningful data exists. These “first believers” do more than just provide capital; they often set the entire trajectory for a startup’s success. Bringing together experts in company formation and pre-seed investing, this session details what convinces them to take the initial leap and how they evaluate raw talent over metrics to build institutional-grade credibility.

INVESTOR SPEAKERS

Raj Airey, Founding Partner & Investment Committee Member, Convergence Partners AG



Raj has been in healthcare for 30 years, of which he spent 20 years in MD roles at Pfizer and Baxter in Europe and Asia. He is also a serial entrepreneur, having built and managed 3 high growth businesses. In the last years, Raj has been an active business angel and company builder in the HealthTech space. He is also an Accredited Executive Coach and mentor and member of the expert advisory board of EIT Health, a pan-European public private initiative that fosters innovation with in healthcare with EU, top universities, innovation hubs and large corporates. Raj is a graduate in science from the London University and has received executive education from both Harvard Business School and INSEAD.

Rosie Barnett, Principal, Delin Ventures



Dr. Rosie Barnett is a Partner at Delin Ventures, a private investor focused on early-stage life sciences and health-tech companies with a specialism in advanced therapies. A medical doctor by training, Rosie has held hands-on operating leadership roles across several healthcare startups in health tech and biotech, taking ventures from concept through to clinical readiness and commercial scaling. She holds Board roles with IMMvention Therapeutix, Swarm Oncology, uMed, Turbine.ai and, previously, Ori Biotech. Her focus areas are advanced therapies, AI-enabled drug development, and patient-centric evidence platforms, partnering with founders, institutional investors, family offices, and industry to accelerate transformative innovation. Rosie holds a BMedSci and BMBS from Nottingham University.

Amine Benmoussa, Partner, Karista



Amine has over 15 years of experience in HealthTech investing across in North America and in Europe. Before joining Karista, Amine was as an investor with the BDC Healthcare Fund in Canada leading or co-leading investments in early- to mid-stage healthcare companies. He also served on the boards of several high-growth firms including Circle Cardiovascular Imaging (acq. by Thoma Bravo), Clearwater Clinical (acq. by Sivantos), Clementia Pharmaceuticals (IPO and later acq. by IPSEN), Milestone Pharmaceuticals (IPO), and Swift Medical. At Karista, Amine specializes in healthcare and Digital Health ventures and serves on the boards of RebrAln and SamanTree. He is also actively engaged in the firm's fundraising efforts. Amine holds a Bachelor's in Computer Science from Concordia University and an MBA from HEC Montreal with executive training in PE & VC at Harvard Business School and Corporate Governance at the Rotman School of Management.

Marcos Casado, Investor, Invivo Partners



He holds a degree in Biochemistry from the University of Barcelona and a Master's in Business Management for the Biotechnology and Pharmaceutical Industry. He has built his career in biotech venture capital, investing across the European life sciences ecosystem and supporting the development of high-potential therapeutic companies. Before joining Invivo Partners in 2026, he was part of INKEF Capital in Amsterdam and Inveready in Barcelona, contributing to investments and serving as board observer in multiple biotech companies. At Invivo, he focuses on investing from Fund III in the next generation of transformative therapeutic platforms, translating strong science into scalable companies with meaningful patient impact.

Bettina Ernst, Director, BERNINA BioInvest



Bettina has been investing in healthcare companies for the past 6 years. She also serves on the board of several early-stage biotech companies in Switzerland, on the board of the Swiss Biotech Association, and as a member of the advisory board of the Swiss Entrepreneur Fund and of the Innovation Council of Innosuisse. Bettina is a co-founder of two biotech companies. Prior to her investment and entrepreneurial activities, she worked for 10 years in fundamental immunology in the US (Scripps Research Institute, San Diego, CA) and in Europe. Bettina holds a PhD in immunology and an undergraduate degree in natural science from the Federal Institute of Technology (ETH) in Zurich. Bettina resides in Switzerland.

INVESTOR SPEAKERS

Lina Gaydarova, Investment Manager, Novaterra



Lina Gaydarova is an early stage life sciences investor at Novaterra, Italy's first international pre-seed & seed impact fund. Lina is based in Milan, and actively invests across biopharma in CNS & oncology as well as wet lab diagnostics in EU/US geographies. Prior to Novaterra, Lina was an investor at Bessemer Venture Partners in San Francisco focused on enterprise and healthcare while executing early stage biopharma oncology investments as an LP in an angel fund. Lina's early career was a mix of investment banking & growth equity across infrastructure technology, which she leveraged as a launchpad to break into early stage life sciences investing.

Navin Govind, Partner, Evidence Ventures



Navin Govind is a serial entrepreneur; investor, venture partner at Evidence Ventures, startup advisor, author of several original papers in peer reviewed journals, holds multiple patents and serves as speaker, faculty and advisory boards. Navin is the founder and CEO of Aventyn, a digital therapeutics company focused on delivering clinically validated platform solutions for improving cardio kidney metabolic health. Navin has worked at the intersection of technology, medical device and digital health software platforms for evidencing best in class clinical solutions working with clinician leaders, providers, femtech innovators and global clients. As co-founder of K-Labs, Navin leads strategic health data collaboration initiatives to bring science based; advanced AI enabled deep learning solutions to lower the burden of chronic disease, cost of care, and better health outcomes. Navin is deeply committed to helping shape science based digital health standards, equitable and sustainable policy initiatives for affordable access to quality care. Navin serves as an advisor on the American Heart Association Center for Health Technology and Innovation Business Team and WearTech Applied Research Center.

Irtaza Haider, Managing Partner, K2 BioCapital



Irtaza Haider is Managing Partner at K2 BioCapital, a biotech investment platform focused on helping Asian biotech companies expand into global markets. A former startup operator turned investor, he supports Asian biotechs through licensing, NewCo formation, and strategic partnerships, while advising venture capital funds and family offices on deploying capital into the region's growing biotech sector. Irtaza previously worked in venture capital at OMX Ventures and Transform VC and gained technology transfer experience at Northwestern University. He has successfully exited two startups as an operator. Irtaza holds a Global Executive MBA from the Kellogg School of Management and collaborates with partners including HKUST and PKU Guanghai to bridge biotech innovation across Asia and international markets.

William Hsu, Angel Investor, Life Science Deal Screening Committee, Life Science Angels



Dr. William Hsu, PhD, MBA is a medtech entrepreneur, investor, and advisor focused on building AI-enabled health technologies. With more than 30 years of experience across the U.S. and Singapore, he helps startups bridge innovation, funding, and commercialization between the two regions. An inventor with over 70 patents, he developed algorithms that power implantable ICD and CRT-D devices used worldwide. Dr. Hsu has led high-performing teams in digital health, remote monitoring, and connected care at companies including Guidant (Boston Scientific), BIOTRONIK, Intel, Google Verily, Becton Dickinson, and St. Jude Medical (Abbott). Through WH Consulting, he advises startups, VCs, and healthcare organizations, and he is an active angel investor with NuFund Venture Group and Life Science Angels.

Mohammad Khobreh, Co-Founder and Managing Partner, NG Bio



Mohammad leads the strategic direction of NG Bio, leveraging extensive experience in life sciences investing. He works closely with limited partners and co-investors to maximize portfolio value and frequently collaborates with major pharmaceutical companies and investment funds to share deal flow and identify strategic opportunities. Mohammad is actively involved in guiding portfolio companies through financing strategies, helping them navigate growth and exit planning from an early stage. Before co-founding NG Bio, he was a key life sciences investor at a family office, where he built and led the firm's life sciences investment strategy, achieving more than 3.5x returns in six years. His responsibilities included deal sourcing, due diligence, growth strategy, and exit planning, while also serving on investment committees and portfolio company boards.

INVESTOR SPEAKERS

Carsten Laue, Managing Partner, M2Care



Carsten is an experienced entrepreneur and Managing Partner at M2care Venture Studio, where he leads strategic initiatives and drives innovation in the healthcare sector. With many years of experience as CEO and board member, Carsten has a proven track record in developing successful healthcare startups. His expertise includes strategic management, customer value analysis, fundraising and M&A, with a focus on delivering impactful results. In addition, Carsten is an expert in life sciences and digital health at the Swiss innovation promotion agency Innosuisse.

Chloé Lepretre, Head of Global R&D Search and Evaluation, Servier



Chloé is Global R&D Search and Evaluation Director at Servier, in charge of the scouting for external innovation to nurture the pipeline and research platforms. She has > 15 years experience in life sciences business development sector and joined Servier's Global Business Development Team in 2018 to lead partnering deals in the Discovery and early development space. Before joining Servier, Chloé worked at Onxeo, a listed biotech company in Paris, where she was Program Acquisition Manager, involved in all aspects of scouting, due diligence and deal-making. She has a technology transfer background having previously worked for many years at France Innovation Scientifique et Transfert (FIST), CNRS' TTO, where she was in charge of the protection, valuation and licensing of the inventions coming from the CNRS labs, in the field of neurology and rare diseases. Chloé is a scientist by training, holding a PhD in aging biology from Université Paris Cité, as well as an MBA from IAE Paris Sorbonne Business School.

Mukul Mohanty, Senior Partner, Truffle Capital



Mukul Mohanty is a Senior Partner at Truffle Capital, specializing in driving exits and preparing businesses for future raises. With over 24 years of investment experience, Mukul has extensive expertise in private equity, venture capital, and fundraising strategies. His deep experience in both buy-side and sell-side transactions makes him a critical player in Truffle's medtech portfolio, advancing strategic partnerships and exits. His career spans Europe, Asia, and the US, where he has led and executed multiple campaigns across closed-end funds, Series A and B, and individual mandates. Mukul's strong track record includes building an impressive network of private equity, venture capital, and corporate venture capital groups, alongside leading engagements with institutional investors, family offices, and co-investors. Mukul is a Chartered Accountant, having earned his qualification from the Institute of Chartered Accountants in New Delhi, India in 2003.

Luka Nicin, Investor, Pace Ventures



Luka earned his PhD in cardiovascular science and bioinformatics, followed by research stays on translational biomedicine at Stanford University and a postdoctoral fellowship at Charité Berlin. Complementing his scientific expertise, Luka completed an MBA in biotech entrepreneurship. As the founder of a biopharma consultancy, Luka led science-driven R&D strategies across the drug development value chain, across multiple therapeutic areas and modalities. He provided commercial positioning, market profiling, and portfolio strategy services, and guided clinical development from indication selection to trial design. At Pace Ventures, Luka leverages his scientific background and strategic insight to back innovative health and climate ventures.

Joseph Oliver, Angel Investor, Stanford Angels of the UK



Joseph Tenzin Oliver is a social entrepreneur working at the intersection of innovation, sustainability and impact. Since 2006, he has advised companies, governments and social enterprises on scaling ethical, technology-led solutions for economic and societal value. Named "The Environmental Trailblazer" by the BBC, his career spans Europe, Asia and North America, including six years in China where he founded a strategic innovation consultancy focused on future trends and sustainable lifestyles. Joseph has spent over a decade designing innovation labs and commercialising artificial intelligence, helping organisations integrate AI into practical business frameworks. He is a Fellow of the Royal Society of the Arts, a British Council Leading Light, and an alumnus of Central Saint Martins, Stanford Graduate School of Business globally.

INVESTOR SPEAKERS



Soyoung Park, General Partner, 1004 Venture Partners

Soyoung is a visionary leader who aims to keep people healthy through transformative longevity technologies and healthcare infrastructures. With 15+ years of extensive experience in entrepreneurship and investment, Soyoung has invested in 20+ emerging life sciences companies and contributed to the exits of 3 companies through acquisitions with 3-5x cash-on-cash return multiples. Soyoung holds a Master of Business Administration from the Fuqua School of Business at Duke University.



Francisco Pinto, Partner, Bynd Venture Capital

Francisco Ferreira Pinto is Partner and Executive Director at Bynd Venture Capital, an Iberian venture capital firm with more than 35 active investments across multiple funds. Since joining the executive team in 2014, he has played a key role in the setup and management of the firm's funds, focusing on pre-seed and seed-stage companies in IT/digital, consumer goods, and sustainability with strong connections to Portugal or Spain. Francisco is also a Board Member of Investors Portugal, the Portuguese Early Stage Investment Association. Prior to venture capital, he spent over five years at Deloitte in Portugal and Angola, leading consulting projects across energy, transportation, and tourism. He holds a Master's degree in Engineering and Industrial Management and completed The Lisbon MBA.



Bibi Sattar Marques, Partner, Buenavista Equity Partners

Bibi is Partner and Board Member at Buenavista Equity Partners Portugal, where she leads the development of the firm's venture capital activities and supports its Iberian growth strategy. With more than 18 years of experience in the financial sector, she brings deep expertise in financial auditing, corporate finance, and regulation, gained through roles at PwC and ANACOM, including participation in the Regulatory Accounting Group of the Board of European Regulators of Electronic Communications. In 2017, she led the creation of a venture capital platform within a financial institution, launching nine funds with more than €100 million under management within four years. Bibi also contributes to corporate social responsibility initiatives as a member of the GRACE Advisory Board.



Jeff Stinson, Director, HTA

Jeff is the founder and leader of HealthTech Arkansas (HTA), an organization that drives healthcare innovation for the state's leading hospitals, health systems, and physician practices through accelerator programs and internal innovation initiatives. HTA's flagship programs include the HeartX accelerator and the Northwest Arkansas Biodesign Sprints program. Jeff has also founded and led six early-stage investment funds, including the Fund for Arkansas' Future (FAF), the state's first angel investment group, which invested \$10.6 million in 36 Arkansas tech startups across two funds. Previously, he served as director of UALR TechLaunch, the technology transfer office at the University of Arkansas at Little Rock, and later founded the Delta I-Fund. He holds an MBA with honors from Vanderbilt University.



Mercedes Tuin, Partner, Heran Partners

Mercedes has extensive experience in life sciences and medtech innovation. Prior to joining HERAN, she spent seven years at BOM (Brabant Development Agency) where she was responsible for the Health&Care investment division and led a team building one of the Netherlands' most active health investment portfolios. She (co-)led more than a dozen investments in early stage innovative high-growth companies. Known for her strategic mindset and hands-on approach, Mercedes is a trusted investor and coach to founders and passionate about bringing innovation to market. Mercedes holds an MBA from Rotterdam School of Management and a Master's in Biomedical Sciences from VU Amsterdam.

INVESTOR SPEAKERS

Carmel van den Berk, Investment Manager, Brightlands Venture Partners



Carmel is an Investment Manager at BVP (Brightlands Venture Partners), where she focuses on Seed and Series A investments in healthtech, medtech, and enabling technologies across Europe. She brings a hybrid investor-operator perspective shaped by experience across venture capital, healthcare strategy, and company building. Having worked closely with founders from early clinical validation through commercialization, Carmel supports management teams translating complex clinical and operational challenges into simple, scalable solutions for real-world healthcare settings. Prior to joining BVP, Carmel served as Chief of Staff at Coramaze Technologies, a high-growth structural heart med-tech company working at the intersection of strategy, operations, and capital formation. Before that, she was an investor at MTIP, a Swiss-based HealthTech and MedTech fund. She began her career in healthcare strategy consulting at KPMG.

Mariette van der Velden, Managing Partner, Curie Capital



Mariette has 26 years of experience working for and with international life sciences companies developing and selling new medical technologies and medicines. Before working as a Life Science investor, Mariette had 17 years of all round management and business development experience in biotech. This includes many innovative start-up ventures and the international launch of innovative new medicines. During these years Mariette gained in depth experience and expertise in the field through a broad range of companies and products. From 2012 until 2017 Mariette was Senior Investment Manager Life Sciences & Health at the Brabantse Ontwikkelings Maatschappij (BOM). Here Mariette was responsible for the management of up to 13 portfolio companies where she represented the BOM as shareholder and, to a number of these companies, as Board Member. In 2017 Mariette founded family office Curiant, and in 2018 VC fund Curie Capital, together with Han, to invest in pioneering life sciences start-ups.

Giulia Vestri, Partner, Claris Ventures



Giulia is Partner at Claris Ventures. A scientist by training (PhD in Immunology) with an Executive MBA, she brings a background across business development and strategic roles in the pharmaceutical and biotech sectors. Her work has focused on turning strong science into actionable plans across R&D and market contexts. Education: PhD in Immunology; Executive MBA, SDA Bocconi School of Management.

Jerry Wu, Managing Director, Long River Investment (LRI)



Jerry brings over 27 years of experience in healthcare, venture capital, and cross-border investments. Before joining LongRiver, he led over £250 million in investments as Head of Investment at TusPark Holdings UK, a Cambridge-based VC firm. His extensive background includes leadership roles at AstraZeneca, where he drove AI and data-driven clinical research, as well as contributions to EMBL-EBI, the Wellcome Trust Sanger Institute, and the Cambridge Institute for Medical Research.

Yu Zhang, Venture Partner & MD Europe, FaaS Capital



FaaS Capital is a multi-family office and private equity investment management institution connecting China and the world. It is established by the Diligence Capital team and is mainly engaged in family offices businesses, direct investments and private equity related businesses. FaaS Capital team has successfully cooperated with well-known financial institutions, listed companies, family offices and governmental agencies at all levels. In addition to domestic experience in China, our core team has extensive experience in capital markets, private equity investment and investment banking in Europe, North America, Hong Kong, and beyond. Our unique resource system and strong international vision and management experience have laid a solid foundation for FaaS Capital to become a bridge across the global capital markets, and enabled us to build high-quality deal sourcing channels, and provide comprehensive services based on various assets. * Founded in 2009, Diligence Capital is China's top primary market investment management institution and the first domestic market-oriented Fund of Funds manager registered under the National Development and Reform Commission of China. It has now developed into the Top 10 market-oriented FoFs in China.

INNOVATOR'S PITCH CHALLENGE (IPC)

Pitch Company

9:00 - 9:50 AM
SESSION #1
DIAGNOSTICS



AIDDA B.V.



Exalt



MAVATAR

Nephrolyx GmbH

10:00 - 10:50 AM
SESSION #2
MEDICAL DEVICES



DARWIN Biomed



Myonerv



PhotoPill Medical



Spatial Surgical Inc.

11:00 - 11:50 AM
SESSION #3
THERAPEUTICS



Oncovita



Skymab
Biotherapeutics



StimOxyGen

1:00 - 1:50 PM
SESSION #4
DIAGNOSTICS



Aligned Bio



Genomill Health



You2Yourself BV



Ysium Medical

2:00 - 2:50 PM
SESSION #5
THERAPEUTICS



OrHelix
Complix



FcR Therapeutics



MindLab



Ternarx Pty Ltd

3:00 - 3:50 PM
SESSION #6
CELL & GENE THERAPY
PLATFORMS



Adheal



AMETS
BIOTECHNOLOGY



ISPIRON
Biotechnologies



Xintela

4:00 - 4:50 PM
SESSION #7
THERAPEUTICS



Alphyn Biologics



AMPLEIA



TAUC3 BIOLOGICS
LIMITED



Wavefront Therapeutics

9 AM | SESSION 1 - DIAGNOSTICS

Companies in this session present AI-powered diagnostics and digital health platforms that use functional testing and advanced analytics to guide personalized treatment decisions across oncology, kidney disease, and more. The pitches will show how biomedical data is turned into deployable tools for clinicians and researchers.



AIDDA B.V.

AIDDA B.V. is a med-tech spin-off from the University Medical Center Groningen developing AI-driven software to improve efficiency and precision in cancer radiotherapy. Our flagship technology, RadShot, is a patented dose-guided patient positioning system that automates how patients are aligned before radiation treatment. Today, positioning patients in proton therapy takes around 15 minutes per session, creating workflow bottlenecks, limiting patient access, and increasing staffing pressure. RadShot combines CBCT-based synthetic imaging, fast Monte Carlo dose calculations, and AI-driven optimization to determine the optimal treatment position automatically, reducing positioning time to up to five minutes while maintaining clinical accuracy. By dramatically shortening treatment sessions, RadShot can significantly increase the number of patients treated per day without requiring new infrastructure. We are raising funding to complete the full AI-enabled product, obtain regulatory approval, and deploy it in leading proton therapy centers before expanding to the much larger photon radiotherapy market.



Exalt

exalt® is a precision oncology start-up transforming personalized cancer care with its proprietary, high-throughput functional platform, fScreen. Our patented technology measures, at single-cell resolution, how a patient's live tumor cells respond to more than 140 approved cancer drugs, identifying therapies that selectively eliminate malignant cells while sparing healthy tissue. Proof of concept in humans has been demonstrated in the EXALT-1 trial, where functional testing guided personalized treatment decisions and delivered clear clinical benefit in late-stage cancer patients (€0.9M academic funding). The ongoing randomized EXALT-2 trial (125/150 patients enrolled; completion 2026), sponsored with €4M, is further validating clinical utility and health-economic impact. Unlike genomics-based approaches, fScreen provides real-time, actionable insights to improve therapy selection and patient outcomes. exalt® targets the €18 billion global next-generation cancer diagnostics market and is launching its first in-house pilot at the Munich Leukemia Laboratory, positioning fScreen to become a new standard of care in hematologic oncology.



MAVATAR

Mavatar is a global specialist in AI-driven precision medicine solutions for all diseases. Built on over 20 years of scientific research, Mavatar's proprietary DINA (Deep Integrated Network Analysis) framework powers two flagship platforms: Mavatar Discovery for accelerating disease and drug research, and Mavatar Precision for delivering personalized treatment recommendations in clinical care. By creating digital twins of both patients and diseases, Mavatar enables data-driven decisions that improve treatment outcomes, optimize clinical trials, and reduce healthcare waste. Headquartered in Stockholm, Sweden, Mavatar is driving the future of truly personalized, scalable healthcare across all disease areas.



Nephrolyx GmbH

Nephrolyx is a diagnostics and digital health platform company redefining kidney function assessment through precise, real-world GFR measurement. The company combines regulated mGFR diagnostics with a digital nephrology platform to deliver clinically actionable, high-fidelity renal data across healthcare and life sciences. Nephrolyx is commercially active in Europe and entering the U.S. market, serving hospitals, nephrologists, and pharmaceutical partners. Its RUO platform in the U.S. and CE-IVD portfolio in the EU enable immediate deployment in clinical research, transplant medicine, and CKD management. A core strategic pillar is pharma enablement: Nephrolyx improves data quality in clinical trials by replacing imprecise renal surrogates with true functional kidney metrics—supporting better trial design, patient stratification, and regulatory robustness. With recurring revenue models, platform scalability, and strong strategic acquisition relevance, Nephrolyx is building the foundational infrastructure for precision nephrology and next-generation renal diagnostics.

10 AM | SESSION 2 - MEDICAL DEVICE

This session features device innovators advancing robotic mobility support, smart GI capsules, and laser-enabled surgical tools for real-world clinical use. Each pitch focuses on how intelligent hardware and connectivity can deliver safer, more effective interventions for seniors, IBD patients, and complex soft-tissue procedures.



DARWIN Biomed

DARWIN Biomed is a Spanish company developing new generation robotics to enhance mobility and safety for seniors, aiming to prevent falls and promote autonomy. Its flagship product, MICHELANGELO, is an intelligent walker that leverages advanced technology to assist users in risky situations. Its key innovations include:

- Smart Assistance: By analysing digital biomarkers such as hands strength or gait dynamic, it detects risky situations and automatically activates its motorized wheels to assist the user.
- Frictionless Design: No buttons or levers are required, ensuring an intuitive and effortless user experience.
- Continuous Connectivity: Enables real-time monitoring of the user's activity and sends alerts in emergencies, providing continuous monitoring.
- Enhanced Safety: Ensures stability and dynamic support at all times, encouraging safer and more independent mobility.



Myonerv

Myonerv is a breakthrough British neurotechnology solution designed to transform stroke rehabilitation through an active, remote-operated wearable medical device that restores movement in patients with post-stroke upper-limb paralysis (paresis). A wearable, non-invasive neurostimulator that helps retrain movement after stroke by detecting a patient's intention to move and delivering targeted electrical stimulation to augment that movement. This "closed-loop" approach is supported by scientific evidence showing that synchronising stimulation with a person's voluntary effort can enhance neuroplasticity – the brain's ability to rewire and relearn lost movements. Unlike traditional electrical stimulators, Myonerv uses flexible bioelectronic materials to create soft, reusable electrodes that conform comfortably to the arm. The system is designed to be lightweight, easy to apply, and suitable for both clinical and home environments. It will also allow therapists to monitor progress and support patients remotely, helping expand rehabilitation capacity without increasing staff burden.



PhotoPill Medical

PhotoPill Medical is a clinical-stage medical company developing autonomous, disposable electronic capsules that deliver targeted light therapy for inflammatory bowel disease (IBD), with an initial focus on Crohn's disease. The company's, IBD-Cap™, is a swallowable capsule that emits non-ionizing, non-thermal light directly at inflamed bowel segments. This localized, approach is designed to reduce inflammation, promote mucosal healing and modulate gut microbiota, while avoiding the systemic side effects associated with current drug therapies. PhotoPill has demonstrated strong preclinical results and initial clinical efficacy in IBD proctitis patients and has initiated a multicenter clinical study in Crohn's disease patients with the IBD-Cap™. The capsule has received FDA Breakthrough Device designation. Founded by biochemist and Crohn's patient and led by an experienced team in capsule endoscopy and medical device commercialization, PhotoPill holds a robust IP portfolio and aims to offer a safer, cost-effective and scalable alternative or complement to existing IBD medications.



Spatial Surgical Inc.

Spatial Surgical is developing a robotic-assisted surgical device for the millions of patients who cannot be addressed by current minimally invasive methods, including surgical robots, and still undergo open surgery today. The device integrates a soft tissue laser with intraoperative robotic visualization into a single handpiece that surgeons can seamlessly integrate into their practice with minimal learning curve. The laser provides bloodless incision, ablation, and cauterization with less damage than traditional hand tools, while the intraoperative visualization technology provides robotic-assisted capabilities such as surgical site magnification, fluorescence guided surgery, and AI-assisted tissue identification. With its device, Spatial Surgical aims to improve upon the poor clinical outcomes of open surgery, a space that has seen little innovation for decades. The market for device sales is approximately \$3 billion in the U.S. and \$4.5 billion globally. Five robust provisional patent applications have been filed covering the core components of the system's architecture.

11 AM | SESSION 3 - THERAPEUTICS

Oncology companies in this block showcase virus-derived immunotherapies, next-generation ADCs, and hypoxia-targeting nanoparticles aimed at resistant and aggressive tumors. Presenters will highlight preclinical and early clinical data, along with clear development paths toward meaningful survival and quality-of-life gains.



Oncovita

Oncovita is a biotech company developing a disruptive virus-derived immunotherapy to treat multiple types of cancers. Our Measovir™ platform was developed based on the safe and highly immunogenic measles virus vaccine, a vaccine with clinically proven oncolytic potential. This technology utilizes the natural anti-cancer and immunogenic properties of this harmless vaccine, making it a versatile platform to produce effective new cancer treatments and vaccines. Over 10 years of intensive R&D activity has propelled Oncovita to bring forward our first therapeutic vaccine candidate, a genetically modified measles virus with enhanced immuno-oncolytic activity. Our in vitro and in vivo preclinical data demonstrate that this first candidate is active against many types of cancers such as mesothelioma, bladder cancer, ovarian cancer, multiple myeloma and others. We believe that this therapy, based on a bioproduct derived from the safest human pediatric vaccine, will be widely accepted by patients and physicians. This technology will be part of the new and revolutionary generation of cancer treatments that should provide patients and medical doctors with treatment regimens that will not only have a positive impact on survival, but also on quality of life.



Skymab
Biotherapeutics

Skymab Biotherapeutics is a French biotech company spun out from the CEA, developing next-generation antibody–drug conjugates (ADCs) powered by its proprietary, tumor-selective Skylink® linker platform. Skylink is engineered to enhance the therapeutic index by improving tumor selectivity and tolerability through controlled and optimized payload release, while enabling innovative modalities such as dual-payload ADCs. The company's lead program is a first-in-class Topoisomerase I–based ADC. IND-ready, it has demonstrated superior efficacy and an improved safety profile in multiple preclinical models, including treatment-resistant tumors, outperforming established ADC benchmarks.



StimOxyGen

StimOxyGen is a preclinical oncology company developing SGEN-33, a pH-responsive, oxygen-generating nanoparticle designed to overcome tumour hypoxia — a key driver of resistance to radiotherapy and immunotherapy. Hypoxia is particularly prevalent in aggressive solid tumours such as pancreatic cancer where poor oxygenation limits treatment efficacy and worsens patient outcomes. SGEN-33 consists of a calcium peroxide core protected by a proprietary polymer coating that remains stable in normal tissues but degrades in the mildly acidic tumour microenvironment, triggering controlled, localised oxygen release. This transient reoxygenation enhances the effectiveness of standard-of-care treatments without requiring changes to existing clinical protocols. Preclinical studies demonstrate significant tumour oxygenation, improved radiotherapy response, extended survival, and a favourable safety profile. StimOxyGen is advancing toward IND-enabling studies and building a US-led clinical development pathway through engagement with the FDA and collaboration with leading oncology centres (MSK) SGEN-33 has platform potential across multiple solid tumours and combination regimens.

1 PM | SESSION 4 - DIAGNOSTICS

These pitches spotlight platform technologies that make high-sensitivity diagnostics and NGS more scalable, affordable, and preventive. Companies will demonstrate how their biosensing, NGS library prep, and urine-based monitoring platforms can unlock earlier detection and more proactive health management.



Aligned Bio

Aligned Bio AB (www.alignedbio.com) is a Swedish deeptech/health-tech company founded in 2019 working at the interface of nanotechnology and the life sciences. The company has developed novel nanowire manufacturing technologies that enable fabrication of nanowire-based biosensors with single-molecule sensitivity at production costs 10-1000x less than current biosensors. The company can thus provide novel biosensors at prices that can penetrate new markets requiring single molecule sensitivity. High-sensitivity biosensors have broad applications across the life-sciences. The company has demonstrated its wide platform utility for diagnostics (cardiac, CNS, and inflammation biomarkers) and next generation sequencing (NGS). We aim to be the premier supplier of sensing solutions in these sectors.



Genomill Health

Genomill Health is an NGS-driven health technology company transforming next-generation sequencing into scalable, preventive care. At the core of our platform is a proprietary sequencing library preparation technology that makes NGS faster, more cost-efficient, and operationally streamlined - significantly lowering the barriers to genomic diagnostics. By simplifying and optimizing library prep, we reduce turnaround times, minimize complexity, and improve scalability without compromising data quality. This enables broader access to high-quality sequencing across clinical and research settings. We integrate advanced NGS data with clinical insights and analytics to identify risk factors, enable efficient detection, and support personalized prevention strategies. Rather than reacting to disease, Genomill focuses on proactive, data-driven health management. Our mission is to unlock the full potential of genomics by making precision diagnostics more accessible, affordable, and impactful.



You2Yourself BV

You2Yourself (Y2Y) develops a personalized early disease warning system based on urine, called URIMON. More precisely, Y2Y develops methods and algorithms to monitor biomarker profiles in periodic urine samples of individuals, to enable the early detection of life-threatening diseases and enhance chances of cure. To validate its technology, Y2Y has built (since 2019) a unique biobank of sample series that capture the onset of disease, by collecting periodic samples from 5,000 initially healthy individuals. URIMON 1.0 will be market ready in 2027 and will initially be sold as a subscription based model to health conscious individuals. Our end goal is broad application through reimbursement and population screening. Y2Y's ambition is to free the world from late-stage diagnoses, to enable healthy aging at lower costs.



Ysium Medical

Ysium hub simulation. We're building a medical learning platform for healthcare professionals and patients, combining advanced physical simulators with digital and mixed-reality experiences to make clinical training more realistic, accessible, and data-driven. Every year, millions of doctors and nurses graduate without enough hands-on practice — leading to medical errors and missed early detections. Over 20% of blood draws cause hematomas due to poor technique, and 16.6 million women in Spain are at risk of breast cancer, where early detection is critical. The medical simulation market here alone exceeds €500M. Our simulators provide ultra-realistic tactile training, connected to a digital platform for self-learning, performance tracking, and even patient training at home. We've already launched our first products, validated by leading universities, achieving a 60% conversion rate and a community of 2,000 B2C prospects ahead of our e-commerce launch this November.

2 PM | SESSION 5 - THERAPEUTICS

This session gathers drug developers targeting autoimmune inflammation and pain with novel biologics and small-molecule approaches, including next-generation opioids. The pitches emphasize differentiated mechanisms, safety and tolerability strategies, and clear milestones that de-risk progression toward the clinic.



OrHelix's highly versatile Alphabody® platform is a novel class of biologics that crosses bio-barriers, is protease resistant, stable in the stomach, lungs and gut with an inherently favourable safety profile. This enables development of all round superior NextGen biologics, delivered by inhalation or orally – a platform well-positioned to supersede the injectable mAb drug class. Our lead molecule aims to elevate the current SoC in asthma/COPD by offering a safe, once-daily, locally effective, low dose inhalable anti-IL4Ra therapy that avoids lung inflammation. A spin off from Complix N.V., OrHelix boasts particular expertise in AI-enriched protein engineering & entrepreneurship. Our seasoned co-founder team has achieved 9 M&A exits (incl. Ablynx) and 4 IPOs to date.



FcR Therapeutics

FcR Therapeutics is a biotechnology company developing antibody-based therapeutics that modulate Fc receptor signalling to prevent pathogenic antibody-driven inflammation in autoimmune diseases. Fc receptors are central mediators of immune complex activation of myeloid cells, a pathway implicated in multiple severe autoimmune conditions. By selectively blocking these receptors, FcR Therapeutics interrupts inflammatory cascades upstream while preserving broader immune function. The company is advancing a pipeline of biologics targeting FcαRI (CD89) and FcαRI (CD64), with potential applications in diseases such as IgA nephropathy and rheumatoid arthritis. FcR Therapeutics collaborates with global plasma-medicine leader Grifols to leverage their deep expertise in immunoglobulin biology. The company is currently preparing a Series Seed round to deliver two well defined IND candidates by the end of 2026.



MindLab

MindLab is a clinical-stage pain biotechnology company building a next-generation opioid platform starting with MLB-001, a morphine-based, patent-protected analgesic candidate. MLB-001 is designed to deliver morphine-level pain relief while improving the risk–benefit trade-off that has limited traditional morphine use, including the reward and drug-liking dynamics that contribute to misuse risk and the dose-limiting safety burden. MindLab's strategy is capital-efficient development through value-inflection clinical milestones, followed by partnering and out-licensing or strategic transactions.

The logo for Ternarx is a solid orange rectangle with the word 'TERNARX' in white, bold, uppercase letters.

TERNARX

Ternarx Pty Ltd

Ternarx is a pre-clinical therapeutics company building a discovery engine and differentiated pipeline of targeted protein degrader drugs in cancer and immunology. Our lead program in immunology is focused on developing targeted protein degraders against a central mediator of interferon-mediated autoimmune disease, providing a therapeutic intervention for interferon-high rheumatic autoimmune disorders, such as SLE. Ternarx's E3 ligase discovery platform is centred on the rational selection and optimisation of E3 warhead development and aims to enable the next generation of protein degrader drugs. Ternarx is a spin out company from the Walter and Eliza Hall Institute of Medical Research (WEHI).

3 PM | SESSION 6 - CELL & GENE THERAPY PLATFORMS

Companies in this session present advanced therapy programs alongside enabling platforms that support the development and production of biologics and cell & gene therapies. Each pitch focuses on improving precision, manufacturability, and scalability so that next-generation treatments can be brought to patients more efficiently.



Adheal

AdHeal is a medical device venture spinning out from Imperial College London's Department of Bioengineering. Supported by the Royal Academy of Engineering Enterprise Hub, we are developing a transformative platform of tissue adhesives for regenerative medicine. Our lead application addresses the global burden of periodontitis (gum disease), which affects 50% of adults and is linked to systemic conditions like heart disease, diabetes, and Alzheimer's. Our vision is to shift periodontal care from costly, chronic management to a definitive regenerative cure. Our core innovation is a Class IIb tissue adhesive that "glues" detached gum tissue closed, creating an immediate physical seal against bacterial recolonization. By combining this mechanical seal with localized therapeutic delivery, we promote natural tissue regeneration and restore the gingival attachment. AdHeal bridges the gap in early-intervention care, improving long-term health outcomes and reducing the economic burden of advanced periodontal disease.



AMETS
BIOTECHNOLOGY

Amets Biotechnology is a biotech company founded in 2025 focused on developing innovative gene therapies for rare pediatric diseases, with the goal of delivering curative options to children facing severe conditions with no effective treatments. Built on a strong scientific foundation and led by an internationally recognized gene therapy team, the company combines technological excellence, strategic vision, and translational expertise to efficiently advance therapies toward the clinic. Amets specializes in high-precision therapeutic design, leveraging advanced platforms to maximize safety, efficacy, and development feasibility. Its efforts focus on building a robust pipeline designed to address critical unmet medical needs while creating scalable value. By combining scientific innovation, operational rigor, and a global outlook, Amets positions itself as a high-impact emerging player in advanced therapies — aiming to reshape treatment paradigms in rare pediatric diseases while delivering meaningful clinical and social value for patients, families, and investors.



ISPIRON
Biotechnologies

Ispiron Biotechnologies is on a mission to revolutionize biologics manufacturing to expand global access to life-saving therapies. Traditional bioprocesses are fragmented, manual, and incredibly risky. Manufacturers lose 10% of batches, costing up to \$15 million per failure due to delays in detecting deviations. We are developing eeVOLV, an automated, end-to-end platform that handles every upstream step from the seed train to production and clarification in a single unit.

- 40x More Compact: We achieve the productivity of a 1000L tank in just 25L.
- High-cell density Production: we drastically reduce volumes and footprint.
- The eeVOLV core system « Watches, thinks, and reacts » using 4 proprietary pillars : Digital twin, AI-driven analytics, proprietary hardware and a reasoning engine.

Ispiron is led by a proven team having successfully achieved the exit of their first company. The team has secured 3 LoIs from Pharma leaders and biotech, and a lead investor for their 2m€-seed round.



Xintela

Xintela is a clinical-stage biopharma company developing novel allogeneic mesenchymal stem cell (MSC) therapies based on its proprietary stem cell marker technology. For Xintela's best-in-class MSC product XSTEM®, we completed a 2-year Phase I/IIa clinical study in knee osteoarthritis (OA). XSTEM® showed safety and clinical efficacy making it the first and only cell therapy with a durable disease-modifying OA drug effect which is a significant competitive advantage versus all other stem cell therapy products in this indication.

Xintela is seeking collaboration, out-licensing and financing opportunities. XSTEM® differentials:

- XSTEM® consists of homogenous, integrin $\alpha 10\beta 1$ -selected, MSCs with superior potency and consistency
- Clinical data demonstrate strong and sustained pain reduction and improved joint function
- Clinical and preclinical data support a disease modifying potential of XSTEM®
- XSTEM® is protected with granted product patents for all therapeutic uses
- XSTEM® is manufactured in Xintela's own GMP facility

4 AM | SESSION 7 - THERAPEUTICS

This session spans therapies in rare diseases, tau-driven neurodegenerative disorders, inflammatory skin conditions, and acute high-risk cardiovascular events. Pitches will underline first- or best-in-class potential, platform leverage, and clear commercial opportunities across these specialty, high-unmet-need indications.



Alphyn Biologics

Alphyn is using its Zabalafin Drug Platform to develop unique Multi-Target Therapeutics® to be more efficacious and patient tolerable. The Zabalafin Platform is an impactful innovation because it has multiple bioactive compounds with multiple mechanisms of action to treat individual diseases in multiple ways, to be more effective, and to treat multiple diseases. Our Platform drugs have strong safety, side effect, and patient tolerability profiles. Alphyn's topical Zabalafin Hydrogel (ZH) for atopic dermatitis (AD), a \$41B commercial opportunity, is in Phase 2b trials. Based on Phase 2a and interim blinded results, Alphyn believes ZH be the first drug to directly target AD's four key and interconnected problems – itch, inflammation, bacteria, and dry skin. Competitive drugs primarily direct-target only inflammation. Alphyn's ZH for Molluscum Contagiosum (MC), directly treats the multiple disease problems, uniquely killing this virus, itch, inflammation and, in certain patients, dermatitis and bacterial infection with its associated pain.



AMPLEIA

Ampleia is a start up studio dedicated to rare diseases. We incubate early stage projects and finance the first steps of the development of the drug candidate, act as a co-founder of a biotech with the scientists. We have internally project managers who will monitor the first steps of the development plan. We secure additional non-dilutive financings. Our objective is to insure that the biotech will secure a financing round with VCs after 18 to 30 months of incubation.



TAUC3 BIOLOGICS
LIMITED

TauC3 Biologics Limited is a UK-based biotechnology company developing first-in-class disease-modifying immunotherapies for tauopathies, including frontotemporal dementia due to tau (FTD-tau) and progressive supranuclear palsy (PSP), areas of profound unmet medical need with no approved disease-modifying treatments. The company's approach uniquely targets tauC3, an early, irreversible, and highly toxic soluble tau species that drives disease initiation, aggregation, impaired axonal transport, and neurodegeneration. Unlike prior tau immunotherapy programs focused on late-stage pathology or non-pathogenic tau forms, TauC3 Biologics selectively targets the disease-driving biology at its source. Its lead program, TBL-100, is a LifeArc-humanized monoclonal antibody with picomolar affinity and high selectivity for tauC3. TBL-100 is designed to block neuronal reuptake and trans-synaptic spread of toxic tau while reducing intracellular tauC3 reservoirs. The company is advancing TBL-100 through IND-enabling CMC and GLP toxicology studies, supported by a biomarker strategy to enable patient stratification, target engagement, and early pharmacodynamic readouts.



Wavefront Therapeutics

Wavefront Therapeutics is a preclinical biotech focused on addressing areas of high unmet need in myocardial ischemia. By targeting novel biology, Wavefront has developed intra-cellularly targeted peptides that provide first in disease treatments for cardiac arrest and reperfusion injury, with validation through porcine models. With our lead asset completing lead-optimization work in 2026, we anticipate launching first in human trials in 2028 with potential for commercial launch in 2031. Wavefront's three peptides related to the treatment of acute manifestations of myocardial ischemia are the following.

- Peptide A-301 is administered with epinephrine as part of advanced cardiac life support as part of the treatment of a cardiac arrest to increase survival and provide neuroprotective benefits.
- Peptides from our second program (B-201 and B-301) are administered during a primary percutaneous coronary intervention for a ST-elevation myocardial infarction as a means of preventing ischemic reperfusion injury.

ENTREPRENEUR'S WORKSHOPS

9:00 - 9:50 AM

SCIENCE, SIGNAL, AND LEGIBILITY FOR GLOBAL FUNDRAISING



This session confronts a simple truth: great science does not raise capital, signal does. We will examine how investors actually price risk, why fundraising must be run as a disciplined global campaign, and how legibility turns complex science into an investable story.

We will also address a costly mistake: engaging the wrong partnering events and the wrong investors too early. Not every conference, forum, or investor fits every stage of development. Success requires selecting the right venues, building a stage-appropriate global target list, and engaging partners who are structurally aligned with your product. The goal is to replace activity with real transaction momentum.

Dennis Ford, Founder and CEO, Creator of RESI Conference, Architect LSN Labs

People often describe Dennis Ford as a force multiplier and super connector at the intersection of life sciences, capital, and narrative. With decades of experience in sales, business development, and market positioning, he focuses on finding the straightest line between a technology, its team, and its real market. He is an entrepreneur, author, teacher, and peddler whose work centers on helping early-stage life science companies understand current market realities, align their science with how capital and partners underwrite risk, and structure messaging appropriate to their product and stage of development.



Dennis is the founder and CEO of Life Science Nation (LSN), a global partnering and matching engine that connects early-stage life science companies with qualified capital investors and licensing partners worldwide. He is also the architect of LSN Labs, an entrepreneurial education and global partnering system designed to reduce failure rates in early-stage life sciences by building two-way bridges between regional ecosystems and the global life science arena. He is the creator of the RESI Conference Series, the leading international investor and strategic partner event for early-stage life sciences, connecting emerging technologies with qualified global capital and licensing partners.

Dennis focuses on helping founders craft clear, easily understood narratives that explain their product, its market, and its distinct value in terms that investors and partners can quickly grasp. He is the author of *The Peddler's Prerogative* and *The Life Science Executive's Fund Raising Manifesto* and is currently working on a new book, *From Science to Signal*, focused on de-risking and packaging early-stage life science for global partnering. He is based in Cambridge, Massachusetts.

Greg Mannix, VP of International Business Development, Life Science Nation

Greg Mannix is Vice President of International Business Development at Life Science Nation. After graduating from the University of California, he moved to Europe where he began a career in the life sciences and obtained a Master's degree from IE Business School in Madrid. He has extensive experience in sales and marketing management in large medical device corporations and small start-ups alike, giving Greg a well-rounded international experience in the healthcare field. He has worked extensively in Europe, North America and Latin America and he speaks English, Spanish and French. Greg relocated to Boston 6 years ago to set up the US affiliate for an early-stage Med-tech company from Spain and he immediately took to the vibrant startup community there. Working for LSN is a great way to stay involved in that exciting space.



10:00 - 10:50 AM

TALES FROM THE ROAD

Biotech and MedTech Innovators on their Fundraising Journey



The industry has quickly adapted to a “new normal” – entrepreneurs and investors meet virtually over digital platforms to discuss potential investment opportunities, and it is not uncommon to see entrepreneurs raise capital from investors they have never met before in person. That said, there is no doubt that the fundraising journey continues to be challenging for many. In this panel, you will be able to hear fellow entrepreneurs share their experiences, from successes to challenges. This panel will discuss the following topics and more:

- What are some of the greatest challenges entrepreneurs have faced, especially during the pandemic, and how were they overcome?
- How did entrepreneurs identify investors that fit their technology?
- What are some misconceptions entrepreneurs had about the early-stage investment landscape?

Furthermore, entrepreneurs will share unique tips and insights they have gained from their fundraising experiences, and how others can work their way towards a more successful campaign.

11:00 - 11:50 AM

EIC FUNDING OPPORTUNITIES OVERVIEW

European
Innovation
Council



1:00 - 1:50 PM

COMPANY VALUATION FOR FUNDRAISING



Valuation is a key aspect of fundraising. An average value assumption for each company in a specific financing stage just does not do it anymore. For entrepreneurs, as for investors, its important to understand the value drivers of a company. We are looking at the financing trends of the last years, discuss dos and don'ts when speaking with investors and look at how to value a life science company with no revenues.

Patrik Frei, Founder & CEO, Venture Valuation AG, Switzerland



Dr. Patrik Frei is the founder and CEO of Venture Valuation AG, a company he established in 1999 to provide independent valuation services for high-growth industries. His first client was Novartis Venture Fund, and he has since conducted over 450 valuations for investors, biotech, pharma, and medtech companies. Patrik earned his degree from the University of St. Gallen and completed his PhD at EPFL Lausanne, focusing on the assessment and valuation of high-growth companies. He has served on the boards of Ineo, Aventron AG, and Ophthalmopharma, where he successfully out-licensed a portfolio of products. His articles have been published in journals such as “Nature Biotechnology” and “Chimia,” and he has authored business publications. Dr. Frei also lectures on valuation at institutions like Seoul National University, EPFL Lausanne, and the University of St. Gallen, offering workshops globally.

2:00 - 2:50 PM

LEGIBILITY, SIGNAL, AND THE REAL WORK BETWEEN SEED AND SERIES B



What European and global investors actually require to underwrite early-stage risk, and how signal is formed across scientific, regulatory, and commercial dimensions.

Karim Galzahr, Managing Partner, OKG Capital



Karim is managing partner at OKG Capital, an early-stage medtech and life science investor focused on the management and diagnosis of serious chronic diseases affecting individuals and burdening healthcare systems. OKG aims to bridge the gap between cutting edge science and clinical practice, operating at the intersection between patient need and long-term financial return. Karim has 30 years of experience in all aspects of finance including M&A, asset management, corporate development and strategic advisory work across the technology sector in general and the medical technology area in particular. Karim acts as advisor and non-executive director to early-stage companies, providing input on finance, strategic partnering, investor relations, hiring and commercial deployment.

3:00 - 3:50 PM

NEGOTIATING TERM SHEETS



4:00 - 4:50 PM

DISCOVERY AND DEVELOPMENT OF INNOVATIVE RARE DISEASE MEDICINES






MEDIA PARTNERS



Want to become a RESI Media Partner? Contact us at Marketing@lifesciencenation.com

The Life Science Executive's FUNDRAISING MANIFESTO

BEST PRACTICES FOR IDENTIFYING CAPITAL IN THE BIOTECH AND MEDTECH ARENAS
by Dennis Ford



Contributors

Robert Cohen, Tom Crosby, Jack Fuller, Nono Hu, Maximilian Kletmann, Gerard O'Connor, Lucy Parkinson, Danielle Silva, and Alejandro Zamorano

ABOUT THE BOOK

A primary objective for life science executives is raising capital. Very often, however, a lack of marketing and sales skills impedes their efforts. Focusing regionally, rather than globally, only compounds the challenge.

The Life Science Executive's Fundraising Manifesto helps scientists understand the fundamental skills needed to brand and market their companies, using a consistent message to achieve compelling results from a fundraising campaign. It teaches you how to aggregate a list of potential global investors that are a fit for your company's products and services. Then it explains how to efficiently and effectively reach out to potential investor targets, start a dialogue that fosters a relationship, and ultimately secure capital allocations.

Raising capital is not a one-time event. It must be an ongoing part of your business strategy. *The Life Science Executive's Fundraising Manifesto* reveals the expertise required to continually fundraise and bring your ideas to market.

FOR MORE INFORMATION

Visit www.FundraisingManifesto.com or visit the Life Science Nation table in the exhibit hall